why choose us

First received: February 27, 2023

Clinical Trial: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Systemic Lupus Erythematosus
Lupus Nephritis

Study Type: INTERVENTIONAL


Official Title: An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Participants With Severe, Refractory Systemic Lupus Erythematosus

Brief Summary: The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.

Read more